Gateway for:

Member Countries

Oral Anti-Tuberculosis Vaccine

#3257


New strategy of anti-tuberculosis BCG vaccination: oral administration in conjunction with heterologous protective antigens prime-boost delivery strategy

Tech Area / Field

  • MED-VAC/Vaccines/Medicine
  • BIO-MIB/Microbiology/Biotechnology
  • BIO-CHM/Biochemistry/Biotechnology
  • BIO-CGM/Cytology, Genetics and Molecular Biology/Biotechnology

Status
8 Project completed

Registration date
18.04.2005

Completion date
01.04.2010

Senior Project Manager
Melnikov V G

Leading Institute
Central Tuberculosis Research Institute, Russia, Moscow

Supporting institutes

  • Institute of Immunological Engineering, Russia, Moscow reg., Lyubuchany

Collaborators

  • Texas A&M University System / Health Science Center, USA, TX, College Station

Project summary

The incidence of tuberculosis (TB) is increasing due to the emergence of multidrug-resistant strains of Mycobacterium tuberculosis and the human immunodeficiency virus/AIDS pandemic. The only vaccine against TB presently available for human use is BCG. The aim of the proposal is to improve the efficacy of BCG vaccination. For this purpose we are going to develop BCG preparations for oral administration able to induce protective immunity against tuberculosis infection in mice. We plan to develop the technology of BCG preparation for oral administration by controlling fraction dispersion, using stabilization replenishments and selecting optimal vaccination doses, in order to avoid possible undesirable aspects of oral BCG administration. We plan also to develop new heterologous prime boost immunization strategies more effective than the currently existing BCG vaccination protocol. To evaluate basic parameters of innate and acquired immune responses following vaccination in order to find out reliable immunological correlates of TB protection, we plan to compare the efficacy of oral and subcutaneous routes of Mycobacterium bovis BCG vaccination with subsequent aerosol, intratracheal and intravenous challenge with Mycobacterium tuberculosis H37Rv in the model of murine tuberculosis. Protection of mice after BCG vaccination would be estimated by mean survival time (MST), bacterial load in organs after infection with M. tuberculosis H37Rv and the level of T-cell immune responses.


Back